MiNK reports complete remission in refractory testicular cancer case

NEW YORK - MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biotech company with a market capitalization of $30.8 million, announced the publication of a case study in Nature’s Oncogene documenting a complete remission in a patient with metastatic testicular cancer following treatment with the company’s iNKT cell therapy, agenT-797. According to InvestingPro data, despite the promising clinical developments, analysts have recently revised earnings expectations downward for the upcoming period.

According to the publication, the patient had previously failed multiple treatments including platinum-based chemotherapy, autologous stem cell transplant, and several immune checkpoint inhibitors. After receiving a single infusion of agenT-797 alongside nivolumab, the patient achieved complete clinical, radiologic, and biochemical remission with no evidence of disease more than two years later.

The company reported that donor iNKT cells remained detectable for up to six months after infusion, and the treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease.

Dr. Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners, called the response "remarkable" in a patient who had exhausted standard and experimental treatments.

This case adds to MiNK’s clinical evidence for agenT-797 in solid tumors. The company previously presented data from its Phase 2 trial in second-line gastric cancer at the 2025 AACR Immuno-Oncology meeting, showing immune activation and early signals of tumor control in patients previously resistant to checkpoint inhibitors.

MiNK Therapeutics is currently enrolling patients in an ongoing Phase 2 trial in gastric cancer, with additional results expected in the coming months, according to the press release statement.

The company’s agenT-797 is an allogeneic invariant natural killer T cell therapy designed to combine innate and adaptive immunity against cancer and other diseases. While the clinical progress is promising, InvestingPro analysis reveals the company faces financial challenges with a negative EBITDA of $9.78 million in the last twelve months. Discover more insights about INKT and 1,400+ other stocks with InvestingPro’s comprehensive research reports, which transform complex financial data into actionable intelligence.

In other recent news, MiNK Therapeutics, Inc. has secured a grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The grant is intended to advance MiNK’s allo-iNKT cell therapy platform, which aims to prevent and treat graft-versus-host disease following hematopoietic stem cell transplantation. This development is part of MiNK’s collaboration with the University of Wisconsin, which brings expertise in transplant immunology to the project. Dr. Jennifer Buell, President and CEO of MiNK Therapeutics, noted that the grant validates the potential of their iNKT platform. Dr. Jenny E. Gumperz from the University of Wisconsin emphasized the unique properties of iNKT cells in modulating immune responses, which could improve long-term outcomes for transplant patients. MiNK Therapeutics is also working on other immune technologies, including T cell receptor-based therapies and neoantigen discovery tools. Their lead asset, AGENT-797, is under clinical development for treating GvHD, solid tumors, and critical pulmonary immune collapse. These recent developments highlight MiNK’s efforts in offering innovative treatments for various conditions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.